View full diagram

  •  
close

What does this mean?

  • Leveraging rare product and device capabilities in lower-risk high-return programmes
  • Focusing on inhaled generics and Vectura enhanced therapies
  • Delivering our pipeline programmes on time and to budget

Why does it matter?

  • The reduction in the overall pipeline risk profile will enable further leverage of Vectura's core capabilities to deliver additional value from lower-risk projects

How are we achieving this?

  • Completion of phase activities within pipeline
  • Extending partnered development of high-potential generic medicines for the US market
  • Taking a selective approach to future novel-partnered development programmes and stopping Vectura investment in early-stage novel molecule development

What does this mean?

  • Simplifying processes and procedures to drive operational efficiency and reduce costs
  • Maximising productivity to manage overall R&D investment in line with guidance

Why does it matter?

  • To enhance productivity to allow the Group both to free up capacity to support future development opportunities and achieve cost reductions through a combination of lower external programme expenditure and a measured reduction in headcount.

How are we achieving this?

  • Delivery of procurement savings using category management principles
  • Implementing continuous improvement programmes with suppliers and contract manufacturing organisations
  • Continued financial discipline across the group

What does this mean?

  • Seeking to partner existing programmes that no longer meet our investment criteria
  • Partnering new generic and enhanced delivery development programmes

Why does it matter?

  • To avoid the high cost, low financial leverage and opportunity cost associated with the commercialisation of single assets

How are we achieving this?

  • Initiation or partnering discussions and seeking partners for devices/formulations to extend our generics pipeline
  • Existing early-stage novel programmes will be out-licensed where the cost, risk and likely returns do not meet our newly defined investment criteria

What does this mean?

  • Leveraging strong and growing cash flows from inhaled market portfolio
  • Continued commitment to capital allocation discipline

Why does it matter?

  • To ensure maximum revenue growth

How are we achieving this?

  • Striving to deliver financial results in line with Board expectations and Operational Excellence savings

What does this mean?

  • Ensuring our culture and behaviour are supportive of our overall strategic objectives
  • Attraction and retention of key talent

Why does it matter?

  • Our culture is supported by a clear set of values and expected behaviours which have been incorporated into all key management frameworks and systems
  • Employee engagement and motivation

How are we achieving this?

  • Continued focus on effective talent development and retention and succession planning

The five priorities
of our strategy

Our strategy is to fully leverage our differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products and through the development of high-quality generic alternatives to branded therapies.

Our priorities against which we will measure our progress are clearly defined.

Find out more about each of our priorities by clicking on the relevant section of our strategy.